RAB22A and cancer: The tumor suppressive actions and chemotherapy sensitivity enhancement activity of miR-204, via the inhibition of RAB22A, an oncogene, has been investigated for multiple cancers including nasopharyngeal carcinoma (Rajan et al., 2021; Yin et al., 2014).